Observing caspofungin for lung infection in people living with HIV
Studies caspofungin as a treatment for Pneumocystis lung infection in adults with HIV.
Plain-language title generated from the registry record
Registry title: Caspofungin for Pneumocystis Pneumonia in PLWHIV.
Key facts
- Where
- Mexico City, MexicoSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT06691321, who can take part
Where in Mexico
- Center for Research in Infectious Diseases (CIENI)Mexico City, MexicoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Instituto Nacional de Enfermedades Respiratorias
- Trial code
- NCT06691321
- Record updated
- 19 November 2024
- Original description
Pneumocystis jirovecii pneumonia is a significant concern in peaple with HIV/AIDS, often severe and potentially fatal. While trimethoprim/sulfamethoxazole remains the primary treatment, safety concerns exist with alternative options. Research on Pneumocystis jirovecii's beta-D glucan composition has prompted investigations into echinocandins like caspofungin, showing promise in murine models and some positive results in human studies. Evaluating caspofungin's efficacy through observational studies is crucial due to safety advantages over current treatments and limited documented data.Read full original descriptionShow less
Efficacy of Caspofungin for Pneumocystis Jirovecii Pneumonia in People Living With HIV/AIDS.
Pneumocystis jirovecii pneumonia is a significant concern in peaple with HIV/AIDS, often severe and potentially fatal. While trimethoprim/sulfamethoxazole remains the primary treatment, safety concerns exist with alternative options. Research on Pneumocystis jirovecii's beta-D glucan composition has prompted investigations into echinocandins like caspofungin, showing promise in murine models and some positive results in human studies. Evaluating caspofungin's efficacy through observational studies is crucial due to safety advantages over current treatments and limited documented data.
Inclusion: Diagnosis of probable or proven PCP, according to its diagnostic classification (refer to classification at the end of this section); Have clinical laboratory and virological diagnostic laboratory studies at the time of admission; Classification criteria for Pneumonia by P. jirovecii according to Robert-Gangneux et al.:; Proven: Confirmation by pathology or microbiology. Possible: Presence of three out of four clinical or radiological criteria. Probable: Presence of one clinical or radiological criterion without another identified microorganism.
Exclusion: Patients who have developed an additional opportunistic lung infection during their hospitalization, other than cytomegalovirus pneumonitis or SARS-CoV-2 pneumonia; With a treatment switch to caspofungin after day 7 of treatment initiation (applies only to group B).